Descripción de negocio
PAION AG is a publicly listed Specialty Pharmaceutical Company headquartered in Aachen (Germany) with further sites in Cambridge (United Kingdom) and New Jersey (USA). PAION's lead substance, Remimazolam, is an intravenous ultra-short-acting anesthetic that is currently in Phase III clinical development for procedural sedation and general anesthesia. Remimazolam has been investigated in more than 1,000 patients worldwide. Remimazolam is designed to complement and improve currently available treatment options for patients requiring sedation and anesthesia. PAION is focusing its clinical development activities on Remimazolam and has initiated pre-commercial activities according to PAION's vision to become an acknowledged “PAIONeer” in sedation and anesthesia.
Consejo de gestión & Consejo de supervisión
| CEO |
| Gregor Siebert |
| Consejo de gestión |
| Sebastian Werner |
| Consejo de supervisión |
| Dr. Karin Louise Dorrepaal, Dr. Markus Leyck Dieken, Dr. Hans Christoph Tanner |
Datos de la empresa
| Nombre: |
PAION AG |
| Dirección: |
Heussstraße 25,D-52078 Aachen |
| Teléfono: |
+49-241-4453-0 |
| Fax: |
+49-241-4453-100 |
| E-mail: |
info@paion.de
|
| Internet: |
www.paion.de/ |
| Industria: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Subsector: |
Pharmaceuticals |
| Fin del año financiero: |
31/12 |
| Acciones de libre circulación: |
88.12% |
| Fecha de OPI: |
10/02/2005 |
